Literature DB >> 1402653

Extensive and selective mutation of a rearranged VH5 gene in human B cell chronic lymphocytic leukemia.

J Cai1, C Humphries, A Richardson, P W Tucker.   

Abstract

B cell chronic lymphocytic leukemia (CLL) is the malignant, monoclonal equivalent of a human CD5+ B cell. Previous studies have shown that the VH and VL genes rearranged and/or expressed in CLL have few and apparently random mutations. However, in this study, we have found that the rearranged VH251 gene, one of the three-membered VH5 family, has extensive and selective mutations in B-CLL cells. Somatic mutation at the nucleotide level is 6.03% in B-CLLs whereas the somatic mutation levels are much lower in CD5+ and CD5- cord B cells, adult peripheral blood B cells, and Epstein-Barr virus-transformed CD5+ B cell lines (0.45, 0.93, and 1.92%, respectively). Complementary determining region 1 (CDR1) mutation in CLLs is particularly prevalent, and interchanges in CDRs often lead to acquisition of charge. Analysis of somatic mutations and mutations to charged residues demonstrated that the mutations in CLLs are highly selected.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1402653      PMCID: PMC2119384          DOI: 10.1084/jem.176.4.1073

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  35 in total

1.  Preferential utilization of conserved immunoglobulin heavy chain variable gene segments during human fetal life.

Authors:  H W Schroeder; J Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

2.  Developmentally controlled and tissue-specific expression of unrearranged VH gene segments.

Authors:  G D Yancopoulos; F W Alt
Journal:  Cell       Date:  1985-02       Impact factor: 41.582

Review 3.  Human immunoglobulin heavy chain genes.

Authors:  J D Capra; P W Tucker
Journal:  J Biol Chem       Date:  1989-08-05       Impact factor: 5.157

Review 4.  CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire.

Authors:  P Casali; A L Notkins
Journal:  Immunol Today       Date:  1989-11

5.  Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes.

Authors:  J V Ravetch; U Siebenlist; S Korsmeyer; T Waldmann; P Leder
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

6.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

Review 7.  Immunologic classification of leukemia and lymphoma.

Authors:  K A Foon; R F Todd
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

8.  Structure and expression of human germline VH transcripts.

Authors:  J E Berman; C G Humphries; J Barth; F W Alt; P W Tucker
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

9.  Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation.

Authors:  M Shlomchik; M Mascelli; H Shan; M Z Radic; D Pisetsky; A Marshak-Rothstein; M Weigert
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

10.  Autoantibodies encoded by the most Jh-proximal human immunoglobulin heavy chain variable region gene.

Authors:  T Logtenberg; F M Young; J H Van Es; F H Gmelig-Meyling; F W Alt
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

View more
  9 in total

1.  Molecular single-cell analysis reveals that CD5-positive peripheral blood B cells in healthy humans are characterized by rearranged Vkappa genes lacking somatic mutation.

Authors:  M Fischer; U Klein; R Küppers
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

2.  IgM-producing chronic lymphocytic leukemia cells undergo immunoglobulin isotype-switching without acquiring somatic mutations.

Authors:  D G Efremov; M Ivanovski; F D Batista; G Pozzato; O R Burrone
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

3.  Repertoire cloning of lupus anti-DNA autoantibodies.

Authors:  P Roben; S M Barbas; L Sandoval; J M Lecerf; B D Stollar; A Solomon; G J Silverman
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

4.  Characterization of a human monoclonal autoantibody directed to cardiolipin/beta 2 glycoprotein I produced by chronic lymphocytic leukaemia B cells.

Authors:  X Mariette; Y Levy; M L Dubreuil; L Intrator; F Danon; J C Brouet
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

5.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

Authors:  F Fais; F Ghiotto; S Hashimoto; B Sellars; A Valetto; S L Allen; P Schulman; V P Vinciguerra; K Rai; L Z Rassenti; T J Kipps; G Dighiero; H W Schroeder; M Ferrarini; N Chiorazzi
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

6.  The VH gene repertoire of splenic B cells and somatic hypermutation in systemic lupus erythematosus.

Authors:  Nicola L W Fraser; Gary Rowley; Max Field; David I Stott
Journal:  Arthritis Res Ther       Date:  2003-02-03       Impact factor: 5.156

7.  Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification.

Authors:  Carmela Gurrieri; Peter McGuire; Hong Zan; Xiao-Jie Yan; Andrea Cerutti; Emilia Albesiano; Steven L Allen; Vincent Vinciguerra; Kanti R Rai; Manlio Ferrarini; Paolo Casali; Nicholas Chiorazzi
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

8.  Lack of extensive mutations in the VH5 genes used in common B cell chronic lymphocytic leukemia.

Authors:  L Z Rassenti; T J Kipps
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

9.  Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells.

Authors:  S Hashimoto; M Dono; M Wakai; S L Allen; S M Lichtman; P Schulman; V P Vinciguerra; M Ferrarini; J Silver; N Chiorazzi
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.